CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia

Authors


Abstract

Inotuzumab ozogamicin achieves high response and molecular remission rates in patients with relapsed/refractory acute lymphoblastic leukemia with tolerable toxicity. It warrants further studies of inotuzumab in combination with chemotherapy or other targeted therapy.

Ancillary